Cargando…

Dose-Response Relationship between Radiation Dose and Loco-regional Control in Patients with Stage II-III Esophageal Cancer Treated with Definitive Chemoradiotherapy

PURPOSE: The correlation between radiation dose and loco-regional control (LRC) was evaluated in patients with stage II-III esophageal cancer treated with definitive concurrent chemoradiotherapy (CRT). MATERIALS AND METHODS: Medical records of 236 stage II-III esophageal cancer patients treated with...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Hyun Ju, Suh, Yang-Gun, Lee, Yong Chan, Lee, Sang Kil, Shin, Sung Kwan, Cho, Byung Chul, Lee, Chang Geol
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Cancer Association 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5512369/
https://www.ncbi.nlm.nih.gov/pubmed/27737537
http://dx.doi.org/10.4143/crt.2016.354
_version_ 1783250474320789504
author Kim, Hyun Ju
Suh, Yang-Gun
Lee, Yong Chan
Lee, Sang Kil
Shin, Sung Kwan
Cho, Byung Chul
Lee, Chang Geol
author_facet Kim, Hyun Ju
Suh, Yang-Gun
Lee, Yong Chan
Lee, Sang Kil
Shin, Sung Kwan
Cho, Byung Chul
Lee, Chang Geol
author_sort Kim, Hyun Ju
collection PubMed
description PURPOSE: The correlation between radiation dose and loco-regional control (LRC) was evaluated in patients with stage II-III esophageal cancer treated with definitive concurrent chemoradiotherapy (CRT). MATERIALS AND METHODS: Medical records of 236 stage II-III esophageal cancer patients treated with definitive CRT at Yonsei Cancer Center between 1994 and 2013 were retrospectively reviewed. Among these, 120 received a radiation dose of < 60 Gy (standard-dose group), while 116 received ≥ 60 Gy (high-dose group). The median doses of radiation in the standard- and high-dose groups were 50.4 and 63 Gy, respectively. Concurrent 5-fluorouracil/cisplatin chemotherapy was administered to most patients. RESULTS: There were no differences in patient characteristics between the two groups except for high Karnofsky performance status and lower-thoracic lesions being more prevalent in the standard-dose group. The median progression-free survival (PFS) and overall survival (OS) times were 13.2 months and 26.2 months, respectively. Patients in the high-dose group had significantly better 2-year LRC (69.1% vs. 50.3%, p=0.002), median PFS (16.7 months vs. 11.7 months, p=0.029), and median OS (35.1 months vs. 22.3 months, p=0.043). Additionally, LRC exhibited a dose-response relationship and the complete response rate was significantly higher in the high-dose group (p=0.006). There were no significant differences in treatment-related toxicities between the groups. CONCLUSION: A higher radiation dose (> 60 Gy) is associated with increased LRC, PFS, and OS in patients with stage II-III esophageal cancer treated with definitive CRT.
format Online
Article
Text
id pubmed-5512369
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Korean Cancer Association
record_format MEDLINE/PubMed
spelling pubmed-55123692017-08-11 Dose-Response Relationship between Radiation Dose and Loco-regional Control in Patients with Stage II-III Esophageal Cancer Treated with Definitive Chemoradiotherapy Kim, Hyun Ju Suh, Yang-Gun Lee, Yong Chan Lee, Sang Kil Shin, Sung Kwan Cho, Byung Chul Lee, Chang Geol Cancer Res Treat Original Article PURPOSE: The correlation between radiation dose and loco-regional control (LRC) was evaluated in patients with stage II-III esophageal cancer treated with definitive concurrent chemoradiotherapy (CRT). MATERIALS AND METHODS: Medical records of 236 stage II-III esophageal cancer patients treated with definitive CRT at Yonsei Cancer Center between 1994 and 2013 were retrospectively reviewed. Among these, 120 received a radiation dose of < 60 Gy (standard-dose group), while 116 received ≥ 60 Gy (high-dose group). The median doses of radiation in the standard- and high-dose groups were 50.4 and 63 Gy, respectively. Concurrent 5-fluorouracil/cisplatin chemotherapy was administered to most patients. RESULTS: There were no differences in patient characteristics between the two groups except for high Karnofsky performance status and lower-thoracic lesions being more prevalent in the standard-dose group. The median progression-free survival (PFS) and overall survival (OS) times were 13.2 months and 26.2 months, respectively. Patients in the high-dose group had significantly better 2-year LRC (69.1% vs. 50.3%, p=0.002), median PFS (16.7 months vs. 11.7 months, p=0.029), and median OS (35.1 months vs. 22.3 months, p=0.043). Additionally, LRC exhibited a dose-response relationship and the complete response rate was significantly higher in the high-dose group (p=0.006). There were no significant differences in treatment-related toxicities between the groups. CONCLUSION: A higher radiation dose (> 60 Gy) is associated with increased LRC, PFS, and OS in patients with stage II-III esophageal cancer treated with definitive CRT. Korean Cancer Association 2017-07 2016-10-06 /pmc/articles/PMC5512369/ /pubmed/27737537 http://dx.doi.org/10.4143/crt.2016.354 Text en Copyright © 2017 by the Korean Cancer Association This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Kim, Hyun Ju
Suh, Yang-Gun
Lee, Yong Chan
Lee, Sang Kil
Shin, Sung Kwan
Cho, Byung Chul
Lee, Chang Geol
Dose-Response Relationship between Radiation Dose and Loco-regional Control in Patients with Stage II-III Esophageal Cancer Treated with Definitive Chemoradiotherapy
title Dose-Response Relationship between Radiation Dose and Loco-regional Control in Patients with Stage II-III Esophageal Cancer Treated with Definitive Chemoradiotherapy
title_full Dose-Response Relationship between Radiation Dose and Loco-regional Control in Patients with Stage II-III Esophageal Cancer Treated with Definitive Chemoradiotherapy
title_fullStr Dose-Response Relationship between Radiation Dose and Loco-regional Control in Patients with Stage II-III Esophageal Cancer Treated with Definitive Chemoradiotherapy
title_full_unstemmed Dose-Response Relationship between Radiation Dose and Loco-regional Control in Patients with Stage II-III Esophageal Cancer Treated with Definitive Chemoradiotherapy
title_short Dose-Response Relationship between Radiation Dose and Loco-regional Control in Patients with Stage II-III Esophageal Cancer Treated with Definitive Chemoradiotherapy
title_sort dose-response relationship between radiation dose and loco-regional control in patients with stage ii-iii esophageal cancer treated with definitive chemoradiotherapy
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5512369/
https://www.ncbi.nlm.nih.gov/pubmed/27737537
http://dx.doi.org/10.4143/crt.2016.354
work_keys_str_mv AT kimhyunju doseresponserelationshipbetweenradiationdoseandlocoregionalcontrolinpatientswithstageiiiiiesophagealcancertreatedwithdefinitivechemoradiotherapy
AT suhyanggun doseresponserelationshipbetweenradiationdoseandlocoregionalcontrolinpatientswithstageiiiiiesophagealcancertreatedwithdefinitivechemoradiotherapy
AT leeyongchan doseresponserelationshipbetweenradiationdoseandlocoregionalcontrolinpatientswithstageiiiiiesophagealcancertreatedwithdefinitivechemoradiotherapy
AT leesangkil doseresponserelationshipbetweenradiationdoseandlocoregionalcontrolinpatientswithstageiiiiiesophagealcancertreatedwithdefinitivechemoradiotherapy
AT shinsungkwan doseresponserelationshipbetweenradiationdoseandlocoregionalcontrolinpatientswithstageiiiiiesophagealcancertreatedwithdefinitivechemoradiotherapy
AT chobyungchul doseresponserelationshipbetweenradiationdoseandlocoregionalcontrolinpatientswithstageiiiiiesophagealcancertreatedwithdefinitivechemoradiotherapy
AT leechanggeol doseresponserelationshipbetweenradiationdoseandlocoregionalcontrolinpatientswithstageiiiiiesophagealcancertreatedwithdefinitivechemoradiotherapy